295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI